This HTML5 document contains 97 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n28http://linked.opendata.cz/resource/drugbank/drug/DB00500/identifier/drugbank/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/mesh/concept/
n17http://linked.opendata.cz/resource/drugbank/company/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00500/identifier/national-drug-code-directory/
foafhttp://xmlns.com/foaf/0.1/
n21http://linked.opendata.cz/resource/drugbank/dosage/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00500/identifier/chemspider/
n7http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n9http://linked.opendata.cz/resource/drugbank/drug/DB00500/identifier/wikipedia/
n11http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00500/identifier/pharmgkb/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n16http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n12http://linked.opendata.cz/ontology/mesh/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00500/identifier/kegg-compound/
n3http://linked.opendata.cz/ontology/drugbank/
n15http://www.drugs.com/cdi/
n14http://linked.opendata.cz/resource/drugbank/property/
n5http://www.rxlist.com/cgi/generic2/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00500/identifier/pubchem-compound/
n20http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00500/identifier/pubchem-substance/
n19http://linked.opendata.cz/resource/atc/
n18http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00500
rdf:type
n3:Drug
n3:description
A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. [PubChem]
n3:dosage
n21:271B602A-363D-11E5-9242-09173F13E4C5 n21:271B602B-363D-11E5-9242-09173F13E4C5 n21:271B602C-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
Biphasic elimination from the plasma consisting of a rapid phase with a half-life of one to 2 hours followed by a slower phase with a half-life of about 5 hours.
n3:indication
For the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis, including the treatment of acute flares long-term management. Also for treatment of juvenile rheumatoid arthritis.
n3:manufacturer
n17:271B6024-363D-11E5-9242-09173F13E4C5 n17:271B6025-363D-11E5-9242-09173F13E4C5 n17:271B6022-363D-11E5-9242-09173F13E4C5 n17:271B6023-363D-11E5-9242-09173F13E4C5 n17:271B6020-363D-11E5-9242-09173F13E4C5 n17:271B6021-363D-11E5-9242-09173F13E4C5 n17:271B601F-363D-11E5-9242-09173F13E4C5
owl:sameAs
n7:DB00500 n11:DB00500
dcterms:title
Tolmetin
adms:identifier
n9:Tolmetin n22:5509 n23:46507060 n24:0093-8815-01 n25:PA451721 n26:C02328 n27:5308 n28:DB00500
n3:mechanismOfAction
The mode of action of tolmetin is not known. However, studies in laboratory animals and man have demonstrated that the anti-inflammatory action of tolmetin is not due to pituitary-adrenal stimulation. Tolmetin inhibits prostaglandin synthetase in vitro and lowers the plasma level of prostaglandin E in man. This reduction in prostaglandin synthesis may be responsible for the anti-inflammatory action. Tolmetin does not appear to alter the course of the underlying disease in man.
n3:packager
n17:271B6014-363D-11E5-9242-09173F13E4C5 n17:271B6017-363D-11E5-9242-09173F13E4C5 n17:271B6018-363D-11E5-9242-09173F13E4C5 n17:271B6015-363D-11E5-9242-09173F13E4C5 n17:271B6016-363D-11E5-9242-09173F13E4C5 n17:271B601E-363D-11E5-9242-09173F13E4C5 n17:271B6019-363D-11E5-9242-09173F13E4C5 n17:271B601D-363D-11E5-9242-09173F13E4C5 n17:271B600F-363D-11E5-9242-09173F13E4C5 n17:271B6012-363D-11E5-9242-09173F13E4C5 n17:271B6013-363D-11E5-9242-09173F13E4C5 n17:271B6010-363D-11E5-9242-09173F13E4C5 n17:271B6011-363D-11E5-9242-09173F13E4C5 n17:271B601C-363D-11E5-9242-09173F13E4C5 n17:271B601A-363D-11E5-9242-09173F13E4C5 n17:271B601B-363D-11E5-9242-09173F13E4C5
n3:synonym
Tolmetino Tolmetin Tolmetina 1-Methyl-5-(4-methylbenzoyl)-pyrrole-2-acetic acid Tolmétine Tolmetinum 5-(P-Toluoyl)-1-methylpyrrole-2-acetic acid 1-Methyl-5-P-toluoylpyrrole-2-acetic acid
n3:toxicity
Symptoms of overdose include lethargy, drowsiness, nausea, vomiting, and epigastric pain.
n3:salt
n12:hasConcept
n13:M0021631
foaf:page
n5:tolmetin.htm n15:tolmetin.html n20:tol1449.shtml
n3:IUPAC-Name
n14:271B6031-363D-11E5-9242-09173F13E4C5
n3:InChI
n14:271B6037-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n14:271B6036-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n14:271B6033-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n14:271B6034-363D-11E5-9242-09173F13E4C5
n3:SMILES
n14:271B6035-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n14:271B6047-363D-11E5-9242-09173F13E4C5 n14:271B602F-363D-11E5-9242-09173F13E4C5
n3:logP
n14:271B6049-363D-11E5-9242-09173F13E4C5 n14:271B602D-363D-11E5-9242-09173F13E4C5 n14:271B6030-363D-11E5-9242-09173F13E4C5
n3:logS
n14:271B602E-363D-11E5-9242-09173F13E4C5
n3:pKa
n14:271B604A-363D-11E5-9242-09173F13E4C5
n18:hasATCCode
n19:M02AA21 n19:M01AB03
n3:H-Bond-Acceptor-Count
n14:271B603D-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n14:271B603E-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n14:271B6038-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n14:271B6039-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n14:271B603B-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n14:271B603A-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n14:271B603C-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly and almost completely absorbed with peak plasma levels being reached within 30-60 minutes after an oral therapeutic dose.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
26171-23-3
n3:category
n3:containedIn
n16:271B6026-363D-11E5-9242-09173F13E4C5 n16:271B6029-363D-11E5-9242-09173F13E4C5 n16:271B6027-363D-11E5-9242-09173F13E4C5 n16:271B6028-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n14:271B6043-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n14:271B6045-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n14:271B6046-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n14:271B6048-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n14:271B6042-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n14:271B6041-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n14:271B6044-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n14:271B6032-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n14:271B603F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n14:271B6040-363D-11E5-9242-09173F13E4C5